TY - JOUR
T1 - Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study
AU - Gómez-Junyent, Joan
AU - Lora-Tamayo, Jaime
AU - Baraia-Etxaburu, Josu
AU - Sánchez-Somolinos, Mar
AU - Iribarren, Jose Antonio
AU - Rodriguez-Pardo, Dolors
AU - Praena-Segovia, Julia
AU - Sorlí, Luisa
AU - Bahamonde, Alberto
AU - Riera, Melchor
AU - Rico, Alicia
AU - López, María Dolores del Toro
AU - Morata, Laura
AU - Cobo, Javier
AU - Falgueras, Luis
AU - Benito, Natividad
AU - Rubio, Elena Muñez
AU - Jover-Sáenz, Alfredo
AU - Pigrau, Carles
AU - Ariza, Javier
AU - Murillo, Oscar
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/26
Y1 - 2021/1/26
N2 - Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting.
AB - Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting.
KW - Implant removal
KW - Outcome
KW - Prosthetic joint infection
KW - Rifampin
KW - Staphylococcus aureus
KW - implant removal
KW - outcome
KW - prosthetic joint infection
KW - rifampin
UR - https://www.mdpi.com/2079-6382/10/2/118
UR - http://www.scopus.com/inward/record.url?scp=85100550952&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/9a74d1b3-fc31-30b3-a37a-1822a21e3ad9/
U2 - https://doi.org/10.3390/antibiotics10020118
DO - https://doi.org/10.3390/antibiotics10020118
M3 - Article
C2 - 33530523
SN - 2079-6382
VL - 10
SP - 1
EP - 13
JO - Antibiotics
JF - Antibiotics
IS - 2
M1 - 118
ER -